 | NEW VISTAS IN THERAPEUTICS: FROM DRUG DESIGN TO GENE THERAPY
Copyright © 2001 by the New York Academy of Sciences
description
Annals of the New York Academy of Sciences 953:157-164 (2001)
© 2001 New York Academy of Sciences
Pharmacological Issues in the Treatment of Tuberculosis
CHARLES A. PELOQUIN
Department of Medicine, National Jewish Medical and Research Center, Denver, Colorado 80206, USA
Schools of Pharmacy and Medicine, University of Colorado, Denver, Colorado 80206, USA
Address for correspondence: Charles A. Peloquin, Pharm.D., Pharmacokinetics Laboratory, Room D-106, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206. Voice: 303-398-1427; fax: 303-270-2229.
peloquinc{at}njc.org
A thorough review of the clinical trial data combined with new in vitro experimental information may make the optimization of dosages of TB drugs possible. Several factors can affect the selection and dosage of TB drugs including hepatic and renal impairment, pregnancy, duration of disease before treatment, and extent of debilitation. Drug interactions and pharmacodynamics must be considered, and their roles are discussed.
Key Words: pharmacology • tuberculosis • dosing regimen • cycloserine • toxicity • therapeutic drug monitoring
This article has been cited by other articles:
|
|
|
|
 
J. Li, J. N. Burzynski, Y.-A. Lee, D. Berg, C. R. Driver, R. Ridzon, and S. S. Munsiff
Use of Therapeutic Drug Monitoring for Multidrug-Resistant Tuberculosis Patients
Chest,
December 1, 2004;
126(6):
1770 - 1776.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Jayaram, S. Gaonkar, P. Kaur, B. L. Suresh, B. N. Mahesh, R. Jayashree, V. Nandi, S. Bharat, R. K. Shandil, E. Kantharaj, et al.
Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of Tuberculosis
Antimicrob. Agents Chemother.,
July 1, 2003;
47(7):
2118 - 2124.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
